Association of Smoking Status with Non-small Cell Lung Cancer Patients Harboring Uncommon Epidermal Growth Factor Receptor Mutation

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Nov 7

PMID 36341427

Authors

How-Wen Ko

Shian-Sen Shie

Chih-Wei Wang

Chi-Tsun Chiu

Chih-Liang Wang

Tsung-Ying Yang

Shou-Chu Chou

Chien-Ying Liu

Chih-Hsi Scott Kuo

Yu-Ching Lin

Li-Fu Li

Cheng-Ta Yang

Chin-Chou Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: Uncommon epidermal growth factor receptor (EGFR) mutations include single and complex mutations. However, the association of the smoking status of patients with uncommon and complex mutations remains unclear.

Methods: This retrospective study evaluates the spectrum of uncommon mutations and investigates the influence of smoking status on the frequency of various uncommon mutations using a multi-institutional medical database.

Results: Between 2010 and 2019, 5,608 non-small cell lung cancer (NSCLC) patients were analyzed. mutations were detected in 3,155 (56.3%) patients. Among the 399 (12.6%) patients with uncommon mutations, 198 had single uncommon and 201 complex mutations, including 87 exon 20 insertions, 79 T790M, 70 complex common, and 52 complex uncommon mutations. For comparison, we also included 402 patients with common mutations. The percentage of ever-smokers was significantly higher in patients with uncommon mutations than in patients with common mutations (25.8% vs. 17.4%, = 0.005). Furthermore, the percentage of ever-smokers was higher in those with a complex mutation than in those with a single uncommon mutation (30.3% vs. 21.2%, = 0.040). Among patients carrying uncommon mutations, ever-smokers had significantly more complex uncommon mutations than never-smokers (22.3% vs. 9.8%, = 0.002). Among patients carrying G719X, L861Q, and S768I, ever-smokers tended to have complex mutations more frequently than never-smokers (64.7% vs. 28.7%, 50.0% vs. 18.7%, 88.9% vs. 81.2%, respectively).

Conclusions: Our study demonstrates not only a comprehensive spectrum of uncommon mutations, but also a positive relationship between smoking status and uncommon mutation frequency, especially complex uncommon mutations. The results suggest that smoking contributes to the development of complex mutations.

Citing Articles

Immunotherapy and PD-L1 Tumor Expression in Moroccan Non-Small Cell Lung Cancer Patients with Various Metastasis.

Aazzane O, Fathi S, Charkaoui M, Acharki A, Sahraoui S, Benchakroun N Asian Pac J Cancer Prev. 2024; 25(8):2841-2852.

PMID: 39205582 PMC: 11495451. DOI: 10.31557/APJCP.2024.25.8.2841.

Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report.

Boukansa S, Mouhrach I, Agy F, El Bardai S, Bouguenouch L, Serraj M PLoS One. 2024; 19(6):e0298721.

PMID: 38837980 PMC: 11152259. DOI: 10.1371/journal.pone.0298721.

Targeted therapeutic options in early and metastatic NSCLC-overview.

Galffy G, Morocz E, Korompay R, Hecz R, Bujdoso R, Puskas R Pathol Oncol Res. 2024; 30:1611715.

PMID: 38605928 PMC: 11006988. DOI: 10.3389/pore.2024.1611715.

Association between cigarette smoking history, metabolic phenotypes, and mutation status in patients with non-small cell lung cancer.

Zhang X, Guo X, Gao Q, Zhang J, Zheng J, Zhao G J Thorac Dis. 2023; 15(10):5689-5699.

PMID: 37969305 PMC: 10636471. DOI: 10.21037/jtd-23-1371.

Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.

Li G, Fang M, Zhou Y, Liu X, Tian P, Mei F Heliyon. 2023; 9(10):e20690.

PMID: 37860534 PMC: 10582297. DOI: 10.1016/j.heliyon.2023.e20690.

References

Alexandrov L, Ju Y, Haase K, Van Loo P, Martincorena I, Nik-Zainal S . Mutational signatures associated with tobacco smoking in human cancer. Science. 2016; 354(6312):618-622. PMC: 6141049. DOI: 10.1126/science.aag0299. View

Attili I, Passaro A, Pisapia P, Malapelle U, de Marinis F . Uncommon Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence. Curr Oncol. 2022; 29(1):255-266. PMC: 8774526. DOI: 10.3390/curroncol29010024. View

Chiu C, Yang C, Shih J, Huang M, Su W, Lai R . Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations. J Thorac Oncol. 2015; 10(5):793-799. DOI: 10.1097/JTO.0000000000000504. View

Zhang B, Wang S, Qian J, Yang W, Qian F, Lu J . Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas. Cancer. 2018; 124(11):2399-2406. DOI: 10.1002/cncr.31329. View

Graham R, Treece A, Lindeman N, Vasalos P, Shan M, Jennings L . Worldwide Frequency of Commonly Detected EGFR Mutations. Arch Pathol Lab Med. 2017; 142(2):163-167. DOI: 10.5858/arpa.2016-0579-CP. View

Pham D, Kris M, Riely G, Sarkaria I, McDonough T, Chuai S . Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol. 2006; 24(11):1700-4. DOI: 10.1200/JCO.2005.04.3224. View

Wu J, Yu C, Chang Y, Yang C, Shih J, Yang P . Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011; 17(11):3812-21. DOI: 10.1158/1078-0432.CCR-10-3408. View

Kauffmann-Guerrero D, Maria Huber R, Reu S, Tufman A, Mertsch P, Syunyaeva Z . NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy. Respiration. 2017; 95(3):169-176. DOI: 10.1159/000484175. View

Shao S, Chan Y, Kao Yang Y, Lin S, Hung M, Chien R . The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf. 2019; 28(5):593-600. DOI: 10.1002/pds.4713. View

10.

Govindan R, Ding L, Griffith M, Subramanian J, Dees N, Kanchi K . Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012; 150(6):1121-34. PMC: 3656590. DOI: 10.1016/j.cell.2012.08.024. View

11.

Mao L, Zhao W, Li X, Zhang S, Zhou C, Zhou D . Mutation Spectrum of From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory. Pathol Oncol Res. 2021; 27:602726. PMC: 8262202. DOI: 10.3389/pore.2021.602726. View

12.

Tseng J, Wang C, Yang T, Chen C, Yang C, Chen K . Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. Lung Cancer. 2015; 90(3):472-6. DOI: 10.1016/j.lungcan.2015.09.024. View

13.

Li H, Hu H, Wang R, Pan Y, Wang L, Li Y . Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther. 2014; 7:513-24. PMC: 3979794. DOI: 10.2147/OTT.S60122. View

14.

OKane G, Bradbury P, Feld R, Leighl N, Liu G, Pisters K . Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer. 2017; 109:137-144. DOI: 10.1016/j.lungcan.2017.04.016. View

15.

Pallis A, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S . 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer. 2007; 97(11):1560-6. PMC: 2360265. DOI: 10.1038/sj.bjc.6604068. View

16.

Tanaka T, Matsuoka M, Sutani A, Gemma A, Maemondo M, Inoue A . Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer. 2009; 126(3):651-5. DOI: 10.1002/ijc.24746. View

17.

Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2):154-62. PMC: 4132036. DOI: 10.1097/JTO.0000000000000033. View

18.

Chang L, Lim C, Chang L, Chen K, Shih J, Yu C . Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. Eur J Cancer. 2019; 119:77-86. DOI: 10.1016/j.ejca.2019.06.025. View

19.

Wu Y, Cheng Y, Zhou X, Lee K, Nakagawa K, Niho S . Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(11):1454-1466. DOI: 10.1016/S1470-2045(17)30608-3. View

20.

Beau-Faller M, Prim N, Ruppert A, Nanni-Metellus I, Lacave R, Lacroix L . Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2013; 25(1):126-31. PMC: 3868323. DOI: 10.1093/annonc/mdt418. View